Irinotecan plus immunotherapy for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or stomach–food-pipe junction adenocarcinoma that cannot be removed with surgery
- You can do daily activities with minimal limits (ECOG performance status 0–1)
- Your blood counts and organ function (kidneys, liver, and bone marrow) are strong enough for chemotherapy
- You have no serious uncontrolled heart problems, no recent stroke, and your heart tests (ECG) are normal
- You are not pregnant or breastfeeding, and you use birth control as instructed during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This trial tests a combination of liposomal irinotecan and albumin-bound paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line chemotherapy. It may be an option if you have already tried a fluorouracil-based treatment.
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
Hear when a new Gastric Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.